mechlorethamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1647 51-75-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mustine
  • mechlorethamine
  • mustargen
  • nitrogen mustard
  • chlormethine
  • mechlorethamine hydrochloride
  • mechlorethamine HCl
A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.
  • Molecular weight: 156.05
  • Formula: C5H11Cl2N
  • CLOGP: 1.20
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 0
  • TPSA: 3.24
  • ALOGS: -0.67
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 15, 1949 FDA RECORDATI RARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site pruritus 438.87 54.54 80 1761 3739 56286487
Application site pain 360.00 54.54 68 1773 3852 56286374
Application site erythema 324.67 54.54 64 1777 4536 56285690
Application site discolouration 234.10 54.54 37 1804 715 56289511
Application site irritation 205.01 54.54 37 1804 1615 56288611
Skin discolouration 160.91 54.54 55 1786 34301 56255925
Pruritus 153.45 54.54 106 1735 316517 55973709
Skin irritation 144.81 54.54 37 1804 8418 56281808
Application site vesicles 114.58 54.54 22 1819 1343 56288883
Erythema 114.33 54.54 68 1773 155871 56134355
Application site dryness 103.31 54.54 15 1826 158 56290068
Therapy non-responder 100.62 54.54 46 1795 61309 56228917
Skin burning sensation 81.49 54.54 25 1816 11006 56279220
Application site discharge 80.60 54.54 12 1829 152 56290074
Application site exfoliation 71.17 54.54 12 1829 348 56289878
Application site inflammation 63.66 54.54 11 1830 370 56289856
Skin hyperpigmentation 60.90 54.54 17 1824 5380 56284846
Cutaneous T-cell lymphoma 55.12 54.54 12 1829 1363 56288863

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site pruritus 479.75 66.97 81 1892 1229 31694142
Application site erythema 421.15 66.97 78 1895 2051 31693320
Application site pain 364.55 66.97 67 1906 1682 31693689
Pruritus 208.10 66.97 116 1857 125051 31570320
Application site irritation 188.80 66.97 33 1940 612 31694759
Skin irritation 182.44 66.97 45 1928 4652 31690719
Application site vesicles 173.70 66.97 30 1943 517 31694854
Therapy non-responder 143.98 66.97 60 1913 33751 31661620
Application site discolouration 125.31 66.97 20 1953 206 31695165
Erythema 120.76 66.97 70 1903 80335 31615036
Cutaneous T-cell lymphoma 110.88 66.97 24 1949 1387 31693984
Skin burning sensation 109.87 66.97 29 1944 3910 31691461
Application site discharge 95.30 66.97 15 1958 140 31695231
Blister 91.81 66.97 38 1935 20898 31674473
Application site burn 83.27 66.97 14 1959 203 31695168
Skin discolouration 83.17 66.97 33 1940 16274 31679097
Application site exfoliation 77.78 66.97 12 1961 97 31695274
Second primary malignancy 76.72 66.97 25 1948 7007 31688364
Application site swelling 75.16 66.97 13 1960 225 31695146
Application site erosion 73.60 66.97 11 1962 70 31695301
Disease progression 67.54 66.97 51 1922 90413 31604958

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site pruritus 907.70 48.13 158 3588 3443 70921255
Application site erythema 741.64 48.13 139 3607 4622 70920076
Application site pain 688.59 48.13 129 3617 4273 70920425
Application site irritation 400.37 48.13 70 3676 1547 70923151
Application site discolouration 338.09 48.13 54 3692 670 70924028
Pruritus 333.79 48.13 213 3533 345347 70579351
Skin irritation 303.64 48.13 76 3670 9833 70914865
Application site vesicles 272.12 48.13 49 3697 1284 70923414
Therapy non-responder 238.65 48.13 104 3642 76811 70847887
Skin discolouration 219.06 48.13 80 3666 37245 70887453
Erythema 216.75 48.13 133 3613 199430 70725268
Skin burning sensation 185.17 48.13 53 3693 11373 70913325
Application site discharge 173.22 48.13 27 3719 282 70924416
Application site dryness 162.80 48.13 24 3722 166 70924532
Application site exfoliation 125.32 48.13 21 3725 355 70924343
Cutaneous T-cell lymphoma 121.64 48.13 28 3718 2525 70922173
Application site swelling 119.23 48.13 22 3724 660 70924038
Disease progression 105.93 48.13 78 3668 156594 70768104
Application site erosion 99.33 48.13 16 3730 209 70924489
Skin hyperpigmentation 99.18 48.13 29 3717 6686 70918012
Application site burn 96.78 48.13 19 3727 797 70923901
Blister 96.12 48.13 62 3684 100464 70824234
Dry skin 94.70 48.13 50 3696 55881 70868817
Application site inflammation 94.24 48.13 17 3729 448 70924250
Application site rash 90.21 48.13 21 3725 1988 70922710
Dermatitis 89.74 48.13 35 3711 19382 70905316
Application site reaction 74.67 48.13 15 3731 708 70923990
Skin exfoliation 72.58 48.13 40 3706 48586 70876112
Application site scab 71.93 48.13 12 3734 197 70924501
Second primary malignancy 61.97 48.13 24 3722 13027 70911671
Application site haemorrhage 55.38 48.13 13 3733 1275 70923423
Scab 54.22 48.13 20 3726 9498 70915200
Cutaneous T-cell lymphoma recurrent 53.92 48.13 8 3738 58 70924640
Lymphomatoid papulosis 53.20 48.13 10 3736 332 70924366

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01AA05 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
ALKYLATING AGENTS
Nitrogen mustard analogues
FDA MoA N0000000236 Alkylating Activity
FDA EPC N0000175558 Alkylating Drug
MeSH PA D000477 Alkylating Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018906 Antineoplastic Agents, Alkylating
MeSH PA D002619 Chemical Warfare Agents
MeSH PA D007509 Irritants
MeSH PA D009676 Noxae
MeSH PA D011042 Poisons
CHEBI has role CHEBI:35610 antineoplastic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic lymphoid leukemia, disease indication 92814006
Chronic myeloid leukemia indication 92818009 DOID:8552
Polycythemia vera indication 109992005
Hodgkin's disease indication 118599009
Non-Hodgkin's lymphoma indication 118601006
Mycosis fungoides indication 118618005
Malignant tumor of lung indication 363358000
Primary cutaneous T-cell lymphoma indication 400122007
Pericardial Malignant Effusions indication
Peritoneal Malignant Effusions indication
Pleural Malignant Effusions indication
Amyloidosis contraindication 17602002 DOID:9120
Hyperuricemia contraindication 35885006 DOID:1920
Acute infectious disease contraindication 63171007
Blood coagulation disorder contraindication 64779008 DOID:1247
Leukopenia contraindication 84828003 DOID:615
Secondary malignant neoplasm of bone marrow contraindication 94217008
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
Granulocytopenic disorder contraindication 417672002
Chemotherapy-Induced Hyperuricemia contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.7 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.016% BASE VALCHLOR HELSINN N202317 Aug. 23, 2013 RX GEL TOPICAL 8501819 March 7, 2026 ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY
EQ 0.016% BASE VALCHLOR HELSINN N202317 Aug. 23, 2013 RX GEL TOPICAL 7872050 July 8, 2029 ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4019808 VUID
N0000147897 NUI
D04872 KEGG_DRUG
4017994 VANDF
4019808 VANDF
C0025033 UMLSCUI
CHEBI:28925 CHEBI
CHEMBL427 ChEMBL_ID
DB00888 DRUGBANK_ID
CHEMBL1201001 ChEMBL_ID
D008466 MESH_DESCRIPTOR_UI
4033 PUBCHEM_CID
586 INN_ID
7218 IUPHAR_LIGAND_ID
55-86-7 SECONDARY_CAS_RN
50D9XSG0VR UNII
155036 RXNORM
1972 MMSL
29634 MMSL
5028 MMSL
d01339 MMSL
002630 NDDF
004816 NDDF
29156002 SNOMEDCT_US
372692002 SNOMEDCT_US
387071000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VALCHLOR HUMAN PRESCRIPTION DRUG LABEL 1 69639-120 GEL 0.01 g TOPICAL NDA 28 sections
VALCHLOR HUMAN PRESCRIPTION DRUG LABEL 1 69639-120 GEL 0.01 g TOPICAL NDA 28 sections